Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $66.48 -1.86%
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
NET INCOME (LOSS): -19.42M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Redburn upgrades Southwest, stays bullish on Delta and United
- Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
